We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.89%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.82B
AUM Growth
+$296M
Cap. Flow
+$80.3M
Cap. Flow %
4.42%
Top 10 Hldgs %
36.79%
Holding
155
New
17
Increased
81
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$21.6M
2
HUM icon
Humana
HUM
+$21.3M
3
TDOC icon
Teladoc Health
TDOC
+$18.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.4M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$9.38M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$56M
2
AMGN icon
Amgen
AMGN
+$5.81M
3
BIIB icon
Biogen
BIIB
+$5.29M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$5.16M
5
MGNX icon
MacroGenics
MGNX
+$4.78M

Sector Composition

Rank Sector Weight
1 Healthcare 91.35%
2 Industrials 1.12%
3 Technology 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYNH
101
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$2.44M 0.13%
+47,200
New +$2.29M
QURE icon
102
uniQure
QURE
$2.84B
$2.29M 0.13%
38,300
+28,300
+283% +$1.26M
PTLA
103
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.16M 0.12%
62,300
+36,650
+143% +$1.06M
ASND icon
104
Ascendis Pharma A/S
ASND
$17.3B
$2.14M 0.12%
+18,200
New +$1.59M
ARNA
105
DELISTED
Arena Pharmaceuticals Inc
ARNA
$2.1M 0.12%
46,917
+16,600
+55% +$761K
GWPH
106
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.08M 0.11%
12,353
+5,924
+92% +$882K
RARE icon
107
Ultragenyx Pharmaceutical
RARE
$2.93B
$2.07M 0.11%
29,800
+7,600
+34% +$434K
FOLD
108
DELISTED
Amicus Therapeutics
FOLD
$2.04M 0.11%
+150,000
New +$1.83M
BIIB icon
109
Biogen
BIIB
$30.2B
$2M 0.11%
8,450
-16,800
-67% -$5.29M
ICPT
110
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.93M 0.11%
17,227
-5,921
-26% -$647K
RGNX icon
111
Regenxbio
RGNX
$568M
$1.9M 0.1%
33,100
+9,800
+42% +$485K
NBIX icon
112
Neurocrine Biosciences
NBIX
$17.4B
$1.78M 0.1%
20,200
-19,850
-50% -$1.66M
ANGO icon
113
AngioDynamics
ANGO
$553M
$1.73M 0.1%
75,700
– –
PODD icon
114
Insulet
PODD
$11.3B
$1.71M 0.09%
18,000
– –
PFE icon
115
Pfizer
PFE
$143B
$1.7M 0.09%
+42,160
New +$1.69M
CELG
116
DELISTED
Celgene Corp
CELG
$1.68M 0.09%
17,788
-639,813
-97% -$56M
AMRX icon
117
Amneal Pharmaceuticals
AMRX
$5.77B
$1.42M 0.08%
100,000
+5,000
+5% +$66.1K
LABD icon
118
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$59.7M
$1.38M 0.08%
+375
New +$1.82M
PTCT icon
119
PTC Therapeutics
PTCT
$6.55B
$1.31M 0.07%
34,700
+13,000
+60% +$436K
MRK icon
120
Merck
MRK
$315B
$1.25M 0.07%
15,720
– –
RDUS
121
DELISTED
Radius Health, Inc.
RDUS
$1.18M 0.06%
+59,100
New +$1.08M
ARRY
122
DELISTED
Array Biopharma Inc
ARRY
$1.18M 0.06%
+48,200
New +$1M
BNFT
123
DELISTED
Benefitfocus, Inc.
BNFT
$1.14M 0.06%
+22,979
New +$1.17M
PINC
124
DELISTED
Premier
PINC
$1.08M 0.06%
31,462
+18,062
+135% +$667K
SRPT icon
125
Sarepta Therapeutics
SRPT
$1.85B
$1.08M 0.06%
9,100
-3,600
-28% -$463K
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2019 Portfolio in Review

As of Q1 2019, Bellevue Group held 155 positions worth $1.82B, up 19% from $1.52B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group deployed $80.3M of net new capital in Q1 2019, opening 17 new positions and adding to 81 existing holdings. Its largest new stake was Avedro, Inc Common Stock: 750,000 shares worth $9.2M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Celgene Corp, an estimated $56M trimmed.

  • Bellevue Group's largest Q1 2019 buy was Avedro, Inc Common Stock: 750,000 shares worth $9.2M.
  • Bellevue Group added most to Evolent Health in Q1 2019, an estimated $21.6M increase.
  • Bellevue Group's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $56M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q1 2019, selling an estimated $3.91M.
  • Bellevue Group's ten largest holdings make up 37% of its $1.82B portfolio in Q1 2019.
  • Bellevue Group opened 17 new positions and closed 18 in Q1 2019.
  • Bellevue Group's portfolio value rose 19% quarter-over-quarter to $1.82B.

Based on Bellevue Group's 13F filing for Q1 2019, filed 15 May 2019.